Skip to main content
. Author manuscript; available in PMC: 2024 Feb 1.
Published in final edited form as: Amyotroph Lateral Scler Frontotemporal Degener. 2022 Apr 9;24(1-2):100–107. doi: 10.1080/21678421.2022.2059379

Table 1.

Clinical characteristics of ALS patients and unadjusted associations with ALS survival

Characteristics All
N=135
HR (95%CI)
Age at onset (in years), mean (sd) 56.1 (12.8) 1.04 (1.01, 1.07)b
Sex, n (%)
Male 86 (64%) Reference
Female 49 (36%) 1.40 (0.72, 2.71)
Diagnosis, n (%)
ALS 129 (96%) Reference
ALS-FTSDa 6 (4%) 1.54 (0.47, 5.04)
Site of onset, n (%)
Spinal 99 (73%) Reference
Other 36 (27%) 2.52 (1.31, 4.82)
C9orf72 mutation, n (%)
No 128 (95%) Reference
Yes 7 (5%) 1.52 (0.36, 6.34)
Smoking, n (%)
Never 79 (59%) Reference
Ever 56 (41%) 0.69 [0.36, 1.34]
BMI (kg/m2)
<18, n (%) 4 (3%) 1.52 (0.45, 5.13)
18 to <25, n (%) 60 (44%) Reference
25 to <30, n (%) 44 (33%) 0.48 (0.21, 1.10)
>=30, n (%) 27 (20%) 0.46 (0.17, 1.23)
Diagnostic delay (years), median (25th %, 75th %) 1.0 (0.6, 2.0) 0.71 (0.56, 0.89)b
Baseline ALSFRS-R, median (25th %, 75th %) 37.0 (32.0, 41.0) 0.99 (0.94, 1.03)c
*

Abbreviations: ALS, amyotrophic lateral sclerosis; ALS-FTSD, ALS-frontotemporal spectrum disorder; C9orf72 mutation, chromosome 9 open reading frame 72 repeat expansion; ALSFRS-R, Revised Amyotrophic Lateral Sclerosis Functional Rating Scale; HR, hazard ratio; CI, confidence interval.

a

Includes ALS with frontotemporal dementia, and ALS with behavioral or cognitive impairment.

b

Per year increase

c

Per +1 point difference in ALSFRS-R score